Brain and Central Nervous System Tumors Clinical Trial
Official title:
Magnetic Resonance Correlates of Glioma Tumor Burden
RATIONALE: New imaging procedures such as magnetic resonance imaging may improve the ability
to detect the extent of newly diagnosed cancer.
PURPOSE: Diagnostic study of magnetic resonance imaging to determining the extent of cancer
in patients who have newly diagnosed glioma.
OBJECTIVES: I. Determine whether proton magnetic resonance spectroscopic imaging (1H-MRSI)
and diffusion magnetic resonance imaging (DI) measures of glioma cell burden correlate with
histopathologically measured cell counts in glioma patients who are scheduled to undergo
surgical resection. II. Determine whether 1H-MRSI and DI measures of glioma cell burden are
invariant over the short term (1 week) as steroid dose is increased in these patients.
OUTLINE: Part I: Patients who are scheduled to have surgical resection of brain tumor
undergo conventional magnetic resonance imaging (MRI), proton magnetic resonance
spectroscopic imaging (1H-MRSI), and diffusion magnetic resonance imaging (DI) within 1 week
before resection. Patients undergo conventional MRI within 72 hours after completion of
surgical resection. Image characteristics of the resected tissue are correlated with
histopathological measures. Part II: Patients who have clinical indications for increasing
the dexamethasone dose are treated on part II of the study. Patients are stratified by
status of steroid treatment (steroid naive vs prior steroid management). Patients undergo
conventional MRI, 1H-MRSI, and DI within 2 days before and within 4-7 days after increasing
the dexamethasone dose. Image characteristics on films taken before and after increasing the
dexamethasone dose are compared.
PROJECTED ACCRUAL: A total of 75 patients will be accrued for part I of the study and a
total 40 patients (20 per stratum) will be accrued for part II of the study within 4 years.
;
Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
| Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
| Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
| Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
| Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
| Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
| Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
| Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
| Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
| Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
| Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
| Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
| Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
| Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 | |
| Completed |
NCT00003484 -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
|
Phase 1 | |
| Completed |
NCT00003464 -
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
|
Phase 2 | |
| Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 |